No Data
No Data
Day One Biopharmaceuticals Insider Sold Shares Worth $426,675, According to a Recent SEC Filing
TD Cowen Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.2% and a total average return of 14.3%
TD Cowen Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Express News | Day One Biopharmaceuticals Inc Files for Offering of up to 12.1 Mln Shares by the Selling Stockholders - SEC Filing
A Great Week That Adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) One-year Returns, Institutional Investors Who Own 56% Must Be Happy
Express News | Day One Biopharmaceuticals Inc : JP Morgan Adds Stock to Its Analyst Focus List